All In MedTech

Device Trial Radar · NCT07575191

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Unresectable Locally Advanced Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Smartwise Sweden ABNot on our public-company list
Sponsor type
Industry
First posted
May 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System. The study will include patients with Locally Advanced Pancreatic Cancer that cannot be removed with surgery. Patients will receive four treatment sessions, given every two weeks, in which Gemcitabine is infused directly into or near the tumor. The study will test up to three increasing dose levels of Gemcitabine (200 mg, 400 mg, and 100 mg). The study will enroll three groups of three patients each. After each group completes treatment, an independent safety committee will review the results to decide whether it is safe to move to the next dose per predefined study criteria. After finishing treatment, patients will be followed for six months. Each patient's total participation in the study will last about 8-9 months. The main goal of the study is to evaluate the safety and feasibility of this treatment approach.

Conditions

  • Pancreatic Cancer Non-resectable

Interventions

  • GemcitabineDrug

    Gemcitabine administered via the Extroducer Infusion Catheter System for targeted delivery.

  • Extroducer Infusion Catheter SystemDevice

    Infusion catheter system for delivery of diagnostic or therapeutic agents into the extravascular space or peripheral vasculature.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extroducer® related Serious Adverse EventsTime frame: From each study treatment until 72 hours post treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Karolinska University Hospital

    Solna, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.